<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01411215</url>
  </required_header>
  <id_info>
    <org_study_id>B1801044</org_study_id>
    <nct_id>NCT01411215</nct_id>
  </id_info>
  <brief_title>A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department</brief_title>
  <acronym>ENBREL NIS CN</acronym>
  <official_title>A Non-Interventional Study of the Treatment With Etanercept in Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) Subjects in Rheumatology Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter and observational study in China, which is designed to
      record the data of RA &amp; AS patients within 52 weeks after rheumatologists decided to
      prescribe etanercept, and evaluate the safety and efficacy of the treatment. All eligible
      subjects agreed to be recruited in the study and can withdraw anytime if they choose so.

      Patients with RA or AS are typically managed by rheumatologists. As this study seeks to
      record the data of RA &amp; AS patient in etanercept and evaluate the safety and efficacy of the
      treatment, patients will be recruited from Rheumatic department. Rheumatologist will be asked
      to build up the database for RA &amp; AS patient surveillance prospectively in outpatient dept,
      which benefits for the patient treatment outcomes evaluation and clinical management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this non-interventional study is to evaluate the safety of
      etanercept in Chinese RA and AS subjects. Total of 600 subjects (300 RA subjects and 300 AS
      subjects) will be enrolled in the study. If the true rate of an adverse event is no less than
      0.5%, with sample size of 600 subjects, this study will have 95% probability to detect at
      least one occurrence of the adverse event. The study prematurely discontinued on January 15,
      2013 due to slow enrollment and low adherence of etanercept. It should be noted that safety
      concerns have not been seen in this study and have not factored into this decision.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    See termination reason in detailed description.
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Had Any Adverse Events (AEs) During 24 Weeks</measure>
    <time_frame>First day of receiving etanercept through 24 weeks</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Had Any AEs During 52 Weeks</measure>
    <time_frame>First day of receiving etanercept through 52 weeks</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Had Any Serious Adverse Events (SAEs) During 24 Weeks</measure>
    <time_frame>Informed consent or signed data privacy statement through 24 weeks</time_frame>
    <description>An SAE was defined as an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Had Any SAEs During 52 Weeks</measure>
    <time_frame>Informed consent or signed data privacy statement through 52 weeks</time_frame>
    <description>An SAE was defined as an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With AEs Per System Organ Class During 24 Weeks</measure>
    <time_frame>First day of receiving etanercept through 24 weeks</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Participants with multiple AEs within a category (system organ class) were counted once within the category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With AEs Per System Organ Class During 52 Weeks</measure>
    <time_frame>First day of receiving etanercept through 52 weeks</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Participants with multiple AEs within a category (system organ class) were counted once within the category.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment of Disease Activity</measure>
    <time_frame>Baseline (Week 0), Week 2, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52</time_frame>
    <description>Physicians indicated on a 0-100 millimeters (mm) visual analogue scale (VAS) to assess the activity of the participant's disease according to the participant's clinical condition, with 0 meaning no disease activity (disease inactive) and 100 meaning extreme disease activity (disease extremely active).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant's Global Assessment (PtGA) of Disease Activity</measure>
    <time_frame>Baseline (Week 0), Week 2, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52</time_frame>
    <description>Participants placed a vertical line on a 0-100 mm VAS to indicate the magnitude of their global disease activity, with 0 meaning no disease activity (disease inactive) and 100 meaning extreme disease activity (disease extremely active).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Score for Pain</measure>
    <time_frame>Baseline (Week 0), Week 2, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52</time_frame>
    <description>Participants placed a mark on a 0-100 mm VAS to indicate the magnitude of pain, with 0 meaning no pain and 100 meaning the most severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Adherence Rate of 1), &lt;50 Percents (%), 2), &gt;=50% and &lt;70%, 3), &gt;=70% and &lt;80%, 4), &gt;=80% and &lt;100%, 5), &gt;=100% and &lt;120%, and 6), &gt;=120%</measure>
    <time_frame>First day of receiving etanercept up to Week 52</time_frame>
    <description>Treatment adherence rate was calculated using the following formula: [Actual dosing/expected dosing on the basis of approved product label] Ã— 100%. Counts of participants by 6 levels of treatment adherence rate: 1), &lt;50%, 2), &gt;=50% and &lt;70%, 3), &gt;=70% and &lt;80%, 4), &gt;=80% and &lt;100%, 5), &gt;=100% and &lt;120%, and 6), &gt;=120%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Association Between Participant's Age and Treatment Adherence Rate</measure>
    <time_frame>First day of receiving etanercept up to Week 52</time_frame>
    <description>Participants were allocated to 5 groups by age as 10 years separately: &lt;20 years, &gt;=20 and &lt;30 years, &gt;=30 and &lt;40 years, &gt;=40 and &lt;50 years, &gt;50 years. The number of participants with treatment adherence rate 1), &lt;50%, 2), &gt;=50% and &lt;70%, 3), &gt;=70% and &lt;80%, 4), &gt;=80% and &lt;100%, 5), &gt;=100% and &lt;120%, and 6), &gt;=120% were provided for each age group described above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Abnormal Laboratory Test Results</measure>
    <time_frame>Baseline (Week 0) up to Week 52</time_frame>
    <description>Number of participants with any abnormal laboratory test results, criteria for abnormalities were complete blood count (CBC) including hemoglobin (&lt;0.8*lower limit of normal[LLN]), mean corpuscular volume (MCV, &lt;0.9*LLN or &gt;1.1*upper limit of normal[ULN]), hematocrit (&lt;0.8*LLN), red blood cell count (&lt;0.8*LLN), platelets (&lt;0.5*LLN or &gt;1.75*ULN), white blood cell count (&lt;0.6*LLN or &gt;1.5*ULN), lymphocytes (&lt;0.8*LLN or &gt;1.2*ULN), neutrophils (&lt;0.8*LLN or &gt;1.2*ULN), basophil (&gt;1.2*ULN), eosinophil (&gt;1.2*ULN), and monocytes (&gt;1.2*ULN); ESR (&gt;1.5*ULN); aspartate aminotransferase (AST,&gt;3.0*ULN); alanine aminotransferase (ALT,&gt;3.0*ULN); blood urea nitrogen (BUN,&gt;1.3*ULN); and creatinine (CRE,&gt;1.3*ULN).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tender Joint Count (TJC) for RA Participants</measure>
    <time_frame>Baseline (Week 0), Week 2, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52</time_frame>
    <description>TJC (28 joints) include the joints of shoulders, elbows, wrists, metacarpophalangeal (MCP), proximal interphalangeal (PIP), and the knees. The joints were assessed for tenderness using the following scale: Present (1), Absent (2), Not Done (3), Not Applicable (4). Artificial joints were not assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swollen Joint Count (SJC) for RA Participants</measure>
    <time_frame>Baseline (Week 0), Week 2, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52</time_frame>
    <description>SJC (28 joints) include the joints of shoulders, elbows, wrists, MCP, PIP, and the knees. The joints were assessed for swelling using the following scale: Present (1), Absent (2), Not Done (3), Not Applicable (4). Artificial joints were not assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score (DAS) Based on 28-joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])</measure>
    <time_frame>Baseline (Week 0), Week 2, Week 4, Week 12, Week 52</time_frame>
    <description>DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) and PtGA of disease activity on a 0-100 mm VAS: DAS28-4 (ESR)=0.56*square root(TJC 28 joints) + 0.28*square root(SJC 28 joints) + 0.70*ln(ESR) + 0.014*PtGA. DAS28-4 (ESR) above 5.1 indicated high disease activity whereas a DAS28-4 (ESR) below 3.2 indicated low disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of RA Participants Had DAS28-4 (ESR) Improvement</measure>
    <time_frame>Week 2, Week 4, Week 8, Week 12, Week 36, Week 52</time_frame>
    <description>Counts of participants had good, moderate and no response to treatment with etanercept. Good response was present DAS28-4 (ESR) &lt;=3.2, DAS28-4 (ESR) improvement from baseline &gt;1.2. Moderate response was 1) present DAS28-4 (ESR) &gt;3.2 and &lt;=5.1, DAS28-4 (ESR) improvement from baseline &gt;1.2, or &gt;0.6 and &lt;=1.2; 2) present DAS28-4 (ESR) &lt;=3.2, DAS28-4 (ESR) improvement from baseline &gt;0.6 and &lt;=1.2; or 3) present DAS28-4 (ESR) &gt;5.1, DAS28-4 (ESR) improvement from baseline &gt; 1.2. No response was 1) DAS28-4 (ESR) improvement from baseline &lt;=0.6 regardless present DAS28-4 (ESR), or 2) present DAS28-4 (ESR) &gt;5.1, DAS28-4 (ESR) improvement from baseline &gt;0.6 and &lt;=1.2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of RA Participants Had Remission of Disease</measure>
    <time_frame>Baseline (Week 0), Week 2, Week 4, Week 8, Week 12, Week 36, Week 52</time_frame>
    <description>Counts of participants had remission of disease. Remission of disease was defined by a DAS28-4 (ESR) &lt;2.6.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">160</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>RA, AS</arm_group_label>
    <description>Rheumatoid arthritis patients Ankylosing spondylitis patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enbrel</intervention_name>
    <description>25mg biweekly or 50mg per week, subcutaneous injection</description>
    <arm_group_label>RA, AS</arm_group_label>
    <other_name>etanercept</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        outpatient RA and AS patients in China
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a confirmed diagnosis of rheumatoid arthritis or ankylosing spondylitis.

          -  Subject has accepted physician's prescription of etanercept in rheumatology
             department.

          -  Subject agreed to be enrolled in the observational study and sign the ICD.

          -  Subject isâ‰¥18 years of age at the time of consent.

          -  Subject is willing and able to understand and complete questionnaires

        Exclusion Criteria:

          -  Presence of active or suspected latent infection including HIV, or any underlying
             disease, including open cutaneous ulcers that could predispose the subject to
             infections.

          -  Immunodeficiency syndromes including Felty syndrome or large granular lymphocyte
             syndrome.

          -  Active tuberculosis (TB) or a history of TB, or findings consistent with previous
             exposure to TB on a chest x-ray (CXR). Investigators must follow China's guidelines
             for appropriate screening and treatment of TB.

          -  History of hypersensitivity to any of the ingredients in either preparation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Daping Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lanzhou University Second Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou University of Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510405</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>No. 199</name>
      <address>
        <city>Haerbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Baotou Medical College</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <zip>014010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital/Department of Rheumatology</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Nantong University</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <zip>226001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Si Chuan Huaxi Hospital/Rheumatology Department</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baotou Central Hospital</name>
      <address>
        <city>Baotou city</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Changning Guanghua Integrative Medicine Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>200052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiaotong University Affiliated Third People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>201900</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xinjiang Uygur Autonomous Region People's Hospital</name>
      <address>
        <city>Urumqi</city>
        <zip>830001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1801044&amp;StudyName=A%20Study%20of%20Rheumatoid%20Arthritis%20Treatment%20with%20Enbrel%20in%20Adult%20Patient%20in%20Outpatient%20Department%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2011</study_first_submitted>
  <study_first_submitted_qc>August 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2011</study_first_posted>
  <results_first_submitted>January 23, 2014</results_first_submitted>
  <results_first_submitted_qc>January 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 6, 2014</results_first_posted>
  <last_update_submitted>January 23, 2014</last_update_submitted>
  <last_update_submitted_qc>January 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>ankylosing spondylitis</keyword>
  <keyword>observational study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rheumatoid Arthritis [RA]</title>
          <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
        </group>
        <group group_id="P2">
          <title>Ankylosing Spondylitis [AS]</title>
          <description>Participants with AS who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="90">1 participant was considered as screen failure and therefore not treated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet entrance criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline participants were all enrolled participants who received at least 1 dose of etanercept.</population>
      <group_list>
        <group group_id="B1">
          <title>Rheumatoid Arthritis [RA]</title>
          <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
        </group>
        <group group_id="B2">
          <title>Ankylosing Spondylitis [AS]</title>
          <description>Participants with AS who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
            <count group_id="B2" value="90"/>
            <count group_id="B3" value="159"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>less than (&lt;) 20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>greater than or equal to (&gt;=) 20 and &lt;30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=30 and &lt;40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=40 and &lt;50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Had Any Adverse Events (AEs) During 24 Weeks</title>
        <description>An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
        <time_frame>First day of receiving etanercept through 24 weeks</time_frame>
        <population>All enrolled participants who received at least 1 dose of etanercept.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis [RA]</title>
            <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ankylosing Spondylitis [AS]</title>
            <description>Participants with AS who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Any Adverse Events (AEs) During 24 Weeks</title>
          <description>An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
          <population>All enrolled participants who received at least 1 dose of etanercept.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Had Any AEs During 52 Weeks</title>
        <description>An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
        <time_frame>First day of receiving etanercept through 52 weeks</time_frame>
        <population>All enrolled participants who received at least 1 dose of etanercept.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis [RA]</title>
            <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ankylosing Spondylitis [AS]</title>
            <description>Participants with AS who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Any AEs During 52 Weeks</title>
          <description>An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
          <population>All enrolled participants who received at least 1 dose of etanercept.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Had Any Serious Adverse Events (SAEs) During 24 Weeks</title>
        <description>An SAE was defined as an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
        <time_frame>Informed consent or signed data privacy statement through 24 weeks</time_frame>
        <population>All enrolled participants who received at least 1 dose of etanercept.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis [RA]</title>
            <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ankylosing Spondylitis [AS]</title>
            <description>Participants with AS who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Any Serious Adverse Events (SAEs) During 24 Weeks</title>
          <description>An SAE was defined as an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
          <population>All enrolled participants who received at least 1 dose of etanercept.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Had Any SAEs During 52 Weeks</title>
        <description>An SAE was defined as an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
        <time_frame>Informed consent or signed data privacy statement through 52 weeks</time_frame>
        <population>All enrolled participants who received at least 1 dose of etanercept.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis [RA]</title>
            <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ankylosing Spondylitis [AS]</title>
            <description>Participants with AS who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Any SAEs During 52 Weeks</title>
          <description>An SAE was defined as an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
          <population>All enrolled participants who received at least 1 dose of etanercept.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With AEs Per System Organ Class During 24 Weeks</title>
        <description>An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Participants with multiple AEs within a category (system organ class) were counted once within the category.</description>
        <time_frame>First day of receiving etanercept through 24 weeks</time_frame>
        <population>All enrolled participants who received at least 1 dose of etanercept.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis [RA]</title>
            <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ankylosing Spondylitis [AS]</title>
            <description>Participants with AS who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With AEs Per System Organ Class During 24 Weeks</title>
          <description>An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Participants with multiple AEs within a category (system organ class) were counted once within the category.</description>
          <population>All enrolled participants who received at least 1 dose of etanercept.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Eye disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General disorders+administration site conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatobiliary disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism and nutrition disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal and connective tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and subcutaneous tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With AEs Per System Organ Class During 52 Weeks</title>
        <description>An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Participants with multiple AEs within a category (system organ class) were counted once within the category.</description>
        <time_frame>First day of receiving etanercept through 52 weeks</time_frame>
        <population>All enrolled participants who received at least 1 dose of etanercept.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis [RA]</title>
            <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ankylosing Spondylitis [AS]</title>
            <description>Participants with AS who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With AEs Per System Organ Class During 52 Weeks</title>
          <description>An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Participants with multiple AEs within a category (system organ class) were counted once within the category.</description>
          <population>All enrolled participants who received at least 1 dose of etanercept.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Eye disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General disorders+administration site conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatobiliary disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism and nutrition disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal and connective tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and subcutaneous tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physicianâ€™s Global Assessment of Disease Activity</title>
        <description>Physicians indicated on a 0-100 millimeters (mm) visual analogue scale (VAS) to assess the activity of the participantâ€™s disease according to the participantâ€™s clinical condition, with 0 meaning no disease activity (disease inactive) and 100 meaning extreme disease activity (disease extremely active).</description>
        <time_frame>Baseline (Week 0), Week 2, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52</time_frame>
        <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were participants who were evaluated for physicianâ€™s global assessment of disease activity. n=number of evaluable participants at the corresponding visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis [RA]</title>
            <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ankylosing Spondylitis [AS]</title>
            <description>Participants with AS who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Physicianâ€™s Global Assessment of Disease Activity</title>
          <description>Physicians indicated on a 0-100 millimeters (mm) visual analogue scale (VAS) to assess the activity of the participantâ€™s disease according to the participantâ€™s clinical condition, with 0 meaning no disease activity (disease inactive) and 100 meaning extreme disease activity (disease extremely active).</description>
          <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were participants who were evaluated for physicianâ€™s global assessment of disease activity. n=number of evaluable participants at the corresponding visit.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0), n=65,82</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4" spread="20.62"/>
                    <measurement group_id="O2" value="60.9" spread="22.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, n=44,59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3" spread="26.33"/>
                    <measurement group_id="O2" value="48.2" spread="29.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, n=35,61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" spread="30.77"/>
                    <measurement group_id="O2" value="44.2" spread="31.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=24,47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" spread="37.39"/>
                    <measurement group_id="O2" value="43.9" spread="30.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=16,34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" spread="35.22"/>
                    <measurement group_id="O2" value="39.2" spread="35.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=7,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" spread="35.18"/>
                    <measurement group_id="O2" value="30.1" spread="30.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36, n=2,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="7.07"/>
                    <measurement group_id="O2" value="19.8" spread="26.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, n=3,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="15.14"/>
                    <measurement group_id="O2" value="16.5" spread="12.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participantâ€™s Global Assessment (PtGA) of Disease Activity</title>
        <description>Participants placed a vertical line on a 0-100 mm VAS to indicate the magnitude of their global disease activity, with 0 meaning no disease activity (disease inactive) and 100 meaning extreme disease activity (disease extremely active).</description>
        <time_frame>Baseline (Week 0), Week 2, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52</time_frame>
        <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were participants who were evaluated for PtGA of disease activity. n=number of evaluable participants at the corresponding visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis [RA]</title>
            <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ankylosing Spondylitis [AS]</title>
            <description>Participants with AS who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Participantâ€™s Global Assessment (PtGA) of Disease Activity</title>
          <description>Participants placed a vertical line on a 0-100 mm VAS to indicate the magnitude of their global disease activity, with 0 meaning no disease activity (disease inactive) and 100 meaning extreme disease activity (disease extremely active).</description>
          <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were participants who were evaluated for PtGA of disease activity. n=number of evaluable participants at the corresponding visit.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0), n=65, 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9" spread="20.27"/>
                    <measurement group_id="O2" value="61.8" spread="21.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, n=42,61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1" spread="27.00"/>
                    <measurement group_id="O2" value="48.9" spread="27.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, n=35, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2" spread="31.16"/>
                    <measurement group_id="O2" value="44.1" spread="30.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=23, 47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="38.10"/>
                    <measurement group_id="O2" value="44.4" spread="31.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=16,33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6" spread="35.19"/>
                    <measurement group_id="O2" value="38.8" spread="35.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=7,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" spread="35.02"/>
                    <measurement group_id="O2" value="32.1" spread="32.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36, n=2,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="7.07"/>
                    <measurement group_id="O2" value="13.5" spread="12.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, n=3,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="20.23"/>
                    <measurement group_id="O2" value="22.5" spread="16.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS Score for Pain</title>
        <description>Participants placed a mark on a 0-100 mm VAS to indicate the magnitude of pain, with 0 meaning no pain and 100 meaning the most severe pain.</description>
        <time_frame>Baseline (Week 0), Week 2, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52</time_frame>
        <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were participants who were evaluated for pain. n=number of evaluable participants at the corresponding visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis [RA]</title>
            <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ankylosing Spondylitis [AS]</title>
            <description>Participants with AS who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Score for Pain</title>
          <description>Participants placed a mark on a 0-100 mm VAS to indicate the magnitude of pain, with 0 meaning no pain and 100 meaning the most severe pain.</description>
          <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were participants who were evaluated for pain. n=number of evaluable participants at the corresponding visit.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0), n=65,84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8" spread="19.56"/>
                    <measurement group_id="O2" value="60.5" spread="23.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, n=42,62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="27.90"/>
                    <measurement group_id="O2" value="47.4" spread="28.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, n=35,60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" spread="32.31"/>
                    <measurement group_id="O2" value="42.7" spread="31.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=23,47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2" spread="38.28"/>
                    <measurement group_id="O2" value="41.7" spread="31.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=16,34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6" spread="35.50"/>
                    <measurement group_id="O2" value="39.7" spread="36.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=7,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" spread="36.52"/>
                    <measurement group_id="O2" value="30.0" spread="30.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36, n=2,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="7.07"/>
                    <measurement group_id="O2" value="20.0" spread="26.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, n=3,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="18.72"/>
                    <measurement group_id="O2" value="17.2" spread="15.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Adherence Rate of 1), &lt;50 Percents (%), 2), &gt;=50% and &lt;70%, 3), &gt;=70% and &lt;80%, 4), &gt;=80% and &lt;100%, 5), &gt;=100% and &lt;120%, and 6), &gt;=120%</title>
        <description>Treatment adherence rate was calculated using the following formula: [Actual dosing/expected dosing on the basis of approved product label] Ã— 100%. Counts of participants by 6 levels of treatment adherence rate: 1), &lt;50%, 2), &gt;=50% and &lt;70%, 3), &gt;=70% and &lt;80%, 4), &gt;=80% and &lt;100%, 5), &gt;=100% and &lt;120%, and 6), &gt;=120%.</description>
        <time_frame>First day of receiving etanercept up to Week 52</time_frame>
        <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were participants who were evaluated for treatment adherence rate; those participants with partial dosing dates were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis [RA]</title>
            <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ankylosing Spondylitis [AS]</title>
            <description>Participants with AS who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Adherence Rate of 1), &lt;50 Percents (%), 2), &gt;=50% and &lt;70%, 3), &gt;=70% and &lt;80%, 4), &gt;=80% and &lt;100%, 5), &gt;=100% and &lt;120%, and 6), &gt;=120%</title>
          <description>Treatment adherence rate was calculated using the following formula: [Actual dosing/expected dosing on the basis of approved product label] Ã— 100%. Counts of participants by 6 levels of treatment adherence rate: 1), &lt;50%, 2), &gt;=50% and &lt;70%, 3), &gt;=70% and &lt;80%, 4), &gt;=80% and &lt;100%, 5), &gt;=100% and &lt;120%, and 6), &gt;=120%.</description>
          <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were participants who were evaluated for treatment adherence rate; those participants with partial dosing dates were excluded.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 50% and &lt;70%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=70% and &lt;80%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=80% and &lt;100%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=100% and &lt;120%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=120%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the Association Between Participant's Age and Treatment Adherence Rate</title>
        <description>Participants were allocated to 5 groups by age as 10 years separately: &lt;20 years, &gt;=20 and &lt;30 years, &gt;=30 and &lt;40 years, &gt;=40 and &lt;50 years, &gt;50 years. The number of participants with treatment adherence rate 1), &lt;50%, 2), &gt;=50% and &lt;70%, 3), &gt;=70% and &lt;80%, 4), &gt;=80% and &lt;100%, 5), &gt;=100% and &lt;120%, and 6), &gt;=120% were provided for each age group described above.</description>
        <time_frame>First day of receiving etanercept up to Week 52</time_frame>
        <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were participants who were evaluated for treatment adherence rate; those participants with partial dosing dates were excluded. n=number of evaluable participants at the corresponding age group.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis [RA]</title>
            <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ankylosing Spondylitis [AS]</title>
            <description>Participants with AS who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Association Between Participant's Age and Treatment Adherence Rate</title>
          <description>Participants were allocated to 5 groups by age as 10 years separately: &lt;20 years, &gt;=20 and &lt;30 years, &gt;=30 and &lt;40 years, &gt;=40 and &lt;50 years, &gt;50 years. The number of participants with treatment adherence rate 1), &lt;50%, 2), &gt;=50% and &lt;70%, 3), &gt;=70% and &lt;80%, 4), &gt;=80% and &lt;100%, 5), &gt;=100% and &lt;120%, and 6), &gt;=120% were provided for each age group described above.</description>
          <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were participants who were evaluated for treatment adherence rate; those participants with partial dosing dates were excluded. n=number of evaluable participants at the corresponding age group.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;20 years (&lt;50%), n=3,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;20 years (&gt;=50% and &lt;70%), n=3,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;20 years (&gt;=70% and &lt;80%), n=3,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;20 years (&gt;=80% and &lt;100%), n=3,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;20 years (&gt;=100% and &lt;120%), n=3,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;20 years (&gt;=120%), n=3,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=20 and &lt;30 years (&lt;50%), n=3,26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=20 and &lt;30 years (&gt;=50% and &lt;70%), n=3,26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=20 and &lt;30 years (&gt;=70% and &lt;80%), n=3,26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=20 and &lt;30 years (&gt;=80% and &lt;100%), n=3,26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=20 and &lt;30 years (&gt;=100% and &lt;120%), n=3,26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=20 and &lt;30 years (&gt;=120%), n=3,26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=30 and &lt;40 years (&lt;50%), n=7,21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=30 and &lt;40 years (&gt;=50% and &lt;70%), n=7,21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=30 and &lt;40 years (&gt;=70% and &lt;80%), n=7,21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=30 and &lt;40 years (&gt;=80% and &lt;100%), n=7,21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=30 and &lt;40 years (&gt;=100% and &lt;120%), n=7,21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=30 and &lt;40 years (&gt;=120%), n=7,21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=40 and &lt;50 years (&lt;50%), n=22,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=40 and &lt;50 years (&gt;=50% and &lt;70%), n=22,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=40 and &lt;50 years (&gt;=70% and &lt;80%), n=22,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=40 and &lt;50 years (&gt;=80% and &lt;100%), n=22,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=40 and &lt;50 years (&gt;=100% and &lt;120%), n=22,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=40 and &lt;50 years (&gt;=120%), n=22,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;50 years (&lt;50%), n=34,9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;50 years (&gt;=50% and &lt;70%), n=34,9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;50 years (&gt;=70% and &lt;80%), n=34,9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;50 years (&gt;=80% and &lt;100%), n=34,9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;50 years (&gt;=100% and &lt;120%), n=34,9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;50 years (&gt;=120%), n=34,9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Abnormal Laboratory Test Results</title>
        <description>Number of participants with any abnormal laboratory test results, criteria for abnormalities were complete blood count (CBC) including hemoglobin (&lt;0.8*lower limit of normal[LLN]), mean corpuscular volume (MCV, &lt;0.9*LLN or &gt;1.1*upper limit of normal[ULN]), hematocrit (&lt;0.8*LLN), red blood cell count (&lt;0.8*LLN), platelets (&lt;0.5*LLN or &gt;1.75*ULN), white blood cell count (&lt;0.6*LLN or &gt;1.5*ULN), lymphocytes (&lt;0.8*LLN or &gt;1.2*ULN), neutrophils (&lt;0.8*LLN or &gt;1.2*ULN), basophil (&gt;1.2*ULN), eosinophil (&gt;1.2*ULN), and monocytes (&gt;1.2*ULN); ESR (&gt;1.5*ULN); aspartate aminotransferase (AST,&gt;3.0*ULN); alanine aminotransferase (ALT,&gt;3.0*ULN); blood urea nitrogen (BUN,&gt;1.3*ULN); and creatinine (CRE,&gt;1.3*ULN).</description>
        <time_frame>Baseline (Week 0) up to Week 52</time_frame>
        <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were participants who were evaluated for laboratory test abnormalities.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis [RA]</title>
            <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ankylosing Spondylitis [AS]</title>
            <description>Participants with AS who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Abnormal Laboratory Test Results</title>
          <description>Number of participants with any abnormal laboratory test results, criteria for abnormalities were complete blood count (CBC) including hemoglobin (&lt;0.8*lower limit of normal[LLN]), mean corpuscular volume (MCV, &lt;0.9*LLN or &gt;1.1*upper limit of normal[ULN]), hematocrit (&lt;0.8*LLN), red blood cell count (&lt;0.8*LLN), platelets (&lt;0.5*LLN or &gt;1.75*ULN), white blood cell count (&lt;0.6*LLN or &gt;1.5*ULN), lymphocytes (&lt;0.8*LLN or &gt;1.2*ULN), neutrophils (&lt;0.8*LLN or &gt;1.2*ULN), basophil (&gt;1.2*ULN), eosinophil (&gt;1.2*ULN), and monocytes (&gt;1.2*ULN); ESR (&gt;1.5*ULN); aspartate aminotransferase (AST,&gt;3.0*ULN); alanine aminotransferase (ALT,&gt;3.0*ULN); blood urea nitrogen (BUN,&gt;1.3*ULN); and creatinine (CRE,&gt;1.3*ULN).</description>
          <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were participants who were evaluated for laboratory test abnormalities.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tender Joint Count (TJC) for RA Participants</title>
        <description>TJC (28 joints) include the joints of shoulders, elbows, wrists, metacarpophalangeal (MCP), proximal interphalangeal (PIP), and the knees. The joints were assessed for tenderness using the following scale: Present (1), Absent (2), Not Done (3), Not Applicable (4). Artificial joints were not assessed.</description>
        <time_frame>Baseline (Week 0), Week 2, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52</time_frame>
        <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were RA participants who were evaluated for TJC. n=number of evaluable participants at the corresponding visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis [RA]</title>
            <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Tender Joint Count (TJC) for RA Participants</title>
          <description>TJC (28 joints) include the joints of shoulders, elbows, wrists, metacarpophalangeal (MCP), proximal interphalangeal (PIP), and the knees. The joints were assessed for tenderness using the following scale: Present (1), Absent (2), Not Done (3), Not Applicable (4). Artificial joints were not assessed.</description>
          <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were RA participants who were evaluated for TJC. n=number of evaluable participants at the corresponding visit.</population>
          <units>Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0), n=68</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="7.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, n=44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, n=34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36, n=2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, n=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swollen Joint Count (SJC) for RA Participants</title>
        <description>SJC (28 joints) include the joints of shoulders, elbows, wrists, MCP, PIP, and the knees. The joints were assessed for swelling using the following scale: Present (1), Absent (2), Not Done (3), Not Applicable (4). Artificial joints were not assessed.</description>
        <time_frame>Baseline (Week 0), Week 2, Week 4, Week 8, Week 12, Week 24, Week 36, Week 52</time_frame>
        <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were RA participants who were evaluated for SJC. n=number of evaluable participants at the corresponding visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis [RA]</title>
            <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Swollen Joint Count (SJC) for RA Participants</title>
          <description>SJC (28 joints) include the joints of shoulders, elbows, wrists, MCP, PIP, and the knees. The joints were assessed for swelling using the following scale: Present (1), Absent (2), Not Done (3), Not Applicable (4). Artificial joints were not assessed.</description>
          <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were RA participants who were evaluated for SJC. n=number of evaluable participants at the corresponding visit.</population>
          <units>Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0), n=68</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, n=44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, n=34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36, n=2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, n=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score (DAS) Based on 28-joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])</title>
        <description>DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) and PtGA of disease activity on a 0-100 mm VAS: DAS28-4 (ESR)=0.56*square root(TJC 28 joints) + 0.28*square root(SJC 28 joints) + 0.70*ln(ESR) + 0.014*PtGA. DAS28-4 (ESR) above 5.1 indicated high disease activity whereas a DAS28-4 (ESR) below 3.2 indicated low disease activity.</description>
        <time_frame>Baseline (Week 0), Week 2, Week 4, Week 12, Week 52</time_frame>
        <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were RA participants who were evaluated for DAS28-4 (ESR). n=number of evaluable participants at the corresponding visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis [RA]</title>
            <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score (DAS) Based on 28-joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])</title>
          <description>DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) and PtGA of disease activity on a 0-100 mm VAS: DAS28-4 (ESR)=0.56*square root(TJC 28 joints) + 0.28*square root(SJC 28 joints) + 0.70*ln(ESR) + 0.014*PtGA. DAS28-4 (ESR) above 5.1 indicated high disease activity whereas a DAS28-4 (ESR) below 3.2 indicated low disease activity.</description>
          <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were RA participants who were evaluated for DAS28-4 (ESR). n=number of evaluable participants at the corresponding visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0), n=55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.57" spread="1.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.03" spread="1.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, n=18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.31" spread="1.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88">Standard deviation cannot be calculated since only 1 participant was analyzed at this visit.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.80" spread="1.702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36, n=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20">Standard deviation cannot be calculated since only 1 participant was analyzed at this visit.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, n=2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.08" spread="2.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of RA Participants Had DAS28-4 (ESR) Improvement</title>
        <description>Counts of participants had good, moderate and no response to treatment with etanercept. Good response was present DAS28-4 (ESR) &lt;=3.2, DAS28-4 (ESR) improvement from baseline &gt;1.2. Moderate response was 1) present DAS28-4 (ESR) &gt;3.2 and &lt;=5.1, DAS28-4 (ESR) improvement from baseline &gt;1.2, or &gt;0.6 and &lt;=1.2; 2) present DAS28-4 (ESR) &lt;=3.2, DAS28-4 (ESR) improvement from baseline &gt;0.6 and &lt;=1.2; or 3) present DAS28-4 (ESR) &gt;5.1, DAS28-4 (ESR) improvement from baseline &gt; 1.2. No response was 1) DAS28-4 (ESR) improvement from baseline &lt;=0.6 regardless present DAS28-4 (ESR), or 2) present DAS28-4 (ESR) &gt;5.1, DAS28-4 (ESR) improvement from baseline &gt;0.6 and &lt;=1.2.</description>
        <time_frame>Week 2, Week 4, Week 8, Week 12, Week 36, Week 52</time_frame>
        <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were participants who were evaluated for DAS28-4 (ESR) improvement. n=number of evaluable participants at the corresponding visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis [RA]</title>
            <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of RA Participants Had DAS28-4 (ESR) Improvement</title>
          <description>Counts of participants had good, moderate and no response to treatment with etanercept. Good response was present DAS28-4 (ESR) &lt;=3.2, DAS28-4 (ESR) improvement from baseline &gt;1.2. Moderate response was 1) present DAS28-4 (ESR) &gt;3.2 and &lt;=5.1, DAS28-4 (ESR) improvement from baseline &gt;1.2, or &gt;0.6 and &lt;=1.2; 2) present DAS28-4 (ESR) &lt;=3.2, DAS28-4 (ESR) improvement from baseline &gt;0.6 and &lt;=1.2; or 3) present DAS28-4 (ESR) &gt;5.1, DAS28-4 (ESR) improvement from baseline &gt; 1.2. No response was 1) DAS28-4 (ESR) improvement from baseline &lt;=0.6 regardless present DAS28-4 (ESR), or 2) present DAS28-4 (ESR) &gt;5.1, DAS28-4 (ESR) improvement from baseline &gt;0.6 and &lt;=1.2.</description>
          <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were participants who were evaluated for DAS28-4 (ESR) improvement. n=number of evaluable participants at the corresponding visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good response (Week 2), n=17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate response (Week 2), n=17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response (Week 2), n=17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good response (Week 4), n=16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate response (Week 4), n=16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response (Week 4), n=16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good response (Week 8), n=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate response (Week 8), n=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response (Week 8), n=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good response (Week 12), n=7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate response (Week 12), n=7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response (Week 12), n=7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good response (Week 36), n=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate response (Week 36), n=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response (Week 36), n=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good response (Week 52), n=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate response (Week 52), n=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No response (Week 52), n=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of RA Participants Had Remission of Disease</title>
        <description>Counts of participants had remission of disease. Remission of disease was defined by a DAS28-4 (ESR) &lt;2.6.</description>
        <time_frame>Baseline (Week 0), Week 2, Week 4, Week 8, Week 12, Week 36, Week 52</time_frame>
        <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were participants who were evaluated for DAS28-4 (ESR). n=number of evaluable participants at the corresponding visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis [RA]</title>
            <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of RA Participants Had Remission of Disease</title>
          <description>Counts of participants had remission of disease. Remission of disease was defined by a DAS28-4 (ESR) &lt;2.6.</description>
          <population>All enrolled participants who received at least 1 dose of etanercept. Participants analyzed were participants who were evaluated for DAS28-4 (ESR). n=number of evaluable participants at the corresponding visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0), n=55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, n=18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36, n=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52, n=2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First day of receiving etanercept through the study period until at least 28 after the last dose of etanercept, for SAE, the start time was when the subject provided informed consent or signed data privacy statement.</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Rheumatoid Arthritis [RA]</title>
          <description>Participants with RA who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
        </group>
        <group group_id="E2">
          <title>Ankylosing Spondylitis [AS]</title>
          <description>Participants with AS who received etanercept 25 mg twice weekly or 50 mg weekly per standard medical practice were observed for 52 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

